Annovis Bio names Mark Guerin as chief financial officer

Annovis Bio Inc. (NYSE: ANVS) appointed Mark Guerin as chief financial officer, the company announced. Guerin brings experience from biotechnology companies including serving as CFO at Onconova Therapeutics, now Traws Pharma Inc. (NASDAQ: TRAW), since 2016.

At Onconova, Guerin managed financing transactions including rights offerings, public offerings, and at-the-market offerings. The company merged with Trawsfynydd Therapeutics in April 2024 to form Traws Pharma, with investments from OrbiMed and Torrey Pines. Traws Pharma completed a $20 million financing round in December 2024.

Before Onconova, Guerin worked as an interim finance executive for private equity portfolio companies and served as CFO at Cardiokine Inc., where he oversaw the company's New Drug Application filing and subsequent sale. He also held positions at Barrier Therapeutics Inc. and began his career at Coopers & Lybrand in Philadelphia.

Guerin holds a bachelor's degree in accounting from DeSales University and maintains CPA, CMA, and CFM certifications.

"I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies," Guerin said in a statement.

Annovis develops treatments for neurodegenerative diseases including Alzheimer's and Parkinson's disease. The company is based in Malvern, Pennsylvania.

You May Also Be Interested In

• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Singularity Future Technology closes $5M registered direct offering
• Sky Century Investment responds to OTC Markets stock promotion inquiry